CliffBio
small molecule

LIDOCAINE

LIDOCAINE

Loss of exclusivity—loss of exclusivity
CompanyNoven Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameLIDOCAINE
Active ingredientLIDOCAINE
Strength5%
Dosage formPATCH
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2020
Marketing statusDISCN

More from Noven Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.